At a glance
ClinicalIndex Comparison RecordN/AActive· 1,046 enrolled
Drug / intervention
anastrozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
In Brief
A clinical study evaluating anastrozole for Estrogen Receptor-positive Breast Cancer and 9 related conditions. Active but no longer recruiting, targeting 1,046 participants across 2 sites.
Detailed Summary
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS). Women with stage I-III breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEstrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/AActive
201320142015201620172018201920202021202220232024202520262027
First PostedApr 2013
Enrollment StartJun 2013
Primary CompletionJun 2022
TodayJul 2026
Study CompletionDec 2026
First PostedApr 5, 2013
Enrollment StartJun 11, 2013
Primary CompletionJun 9, 2022
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 9.0 yearsPosted 13.2 years ago
Interventions
anastrozoledrug
Given PO